Momenta Pharmaceuticals, Inc.
MNTA
MNTA was delisted on the 30th of September, 2020.
159 hedge funds and large institutions have $2.01B invested in Momenta Pharmaceuticals, Inc. in 2018 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 60 increasing their positions, 50 reducing their positions, and 15 closing their positions.
56% more call options, than puts
Call options by funds: $3.86M | Put options by funds: $2.48M
29% more capital invested
Capital invested by funds: $1.56B → $2.01B (+$447M)
20% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 50
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 15
1% less funds holding
Funds holding: 160 → 159 (-1)
0.78% less ownership
Funds ownership: 98.28% → 97.5% (-0.78%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$59.3M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$16.4M |
| 3 |
BlackRock
New York
|
+$10.8M |
| 4 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$7.6M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$7.57M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$58M |
| 2 |
Janus Henderson Group
London,
|
-$15.3M |
| 3 |
State Street
Boston,
Massachusetts
|
-$10.2M |
| 4 |
D.E. Shaw & Co
New York
|
-$7.42M |
| 5 |
TA
Teachers Advisors
New York
|
-$6.83M |
MNTA Hedge Fund Activity: Q3 2018 in Review
159 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Momenta Pharmaceuticals, Inc. (MNTA) for Q3 2018, worth a combined $2.01B — up 29% from $1.56B a quarter earlier.
Fund positioning in MNTA was balanced in Q3 2018: 15 funds opened new positions, 15 closed out, 60 added to existing stakes and 50 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $59.3M. The largest seller was RA Capital Management, cutting an estimated $58M.
- 159 institutional investors held Momenta Pharmaceuticals, Inc. (MNTA) as of Q3 2018, down from 160 in Q2 2018.
- Funds reported $2.01B of Momenta Pharmaceuticals, Inc. stock for Q3 2018, up 29% quarter-over-quarter.
- 15 funds opened new Momenta Pharmaceuticals, Inc. positions in Q3 2018 and 15 closed out, a net change of 0 holders.
- The largest Momenta Pharmaceuticals, Inc. buyer in Q3 2018 was T. Rowe Price Associates, an estimated $59.3M added.
- The largest Momenta Pharmaceuticals, Inc. seller in Q3 2018 was RA Capital Management, an estimated $58M sold.
Based on aggregated 13F filings for Q3 2018.